Rocket Pharmaceuticals Stock (NASDAQ:RCKT)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$16.98

52W Range

$15.97 - $32.52

50D Avg

$18.20

200D Avg

$22.80

Market Cap

$1.53B

Avg Vol (3M)

$827.19K

Beta

1.09

Div Yield

-

RCKT Company Profile


Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

268

IPO Date

Feb 18, 2015

Website

RCKT Performance


RCKT Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-259.66M$-224.34M$-167.25M
Net Income$-245.59M$-219.38M$-169.59M
EBITDA$-259.66M$-213.69M$-163.18M
Basic EPS-$-3.22$-2.68
Diluted EPS-$-3.22$-2.68

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 21Aug 09, 21 | 11:39 PM

Peer Comparison


TickerCompany
PLRXPliant Therapeutics, Inc.
DYNDyne Therapeutics, Inc.
RVMDRevolution Medicines, Inc. Warrant
VRDNViridian Therapeutics, Inc.
MRUSMerus N.V.
LRMRLarimar Therapeutics, Inc.
DAWNDay One Biopharmaceuticals, Inc.
MGTXMeiraGTx Holdings plc
STOKStoke Therapeutics, Inc.
STROSutro Biopharma, Inc.
RGNXREGENXBIO Inc.
REPLReplimune Group, Inc.
SNDXSyndax Pharmaceuticals, Inc.
INZYInozyme Pharma, Inc.
RYTMRhythm Pharmaceuticals, Inc.
PCVXVaxcyte, Inc.
SLDBSolid Biosciences Inc.
CYTKCytokinetics, Incorporated
QUREuniQure N.V.
MIRMMirum Pharmaceuticals, Inc.